{"id":100066,"date":"2024-11-20T13:41:57","date_gmt":"2024-11-20T12:41:57","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/"},"modified":"2024-11-20T15:33:46","modified_gmt":"2024-11-20T14:33:46","slug":"gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/","title":{"rendered":"Gate2Brain receives EMA Orphan Drug Designation for groundbreaking pediatric cancer treatment"},"content":{"rendered":"<p><strong><a href=\"https:\/\/www.pcb.ub.edu\/en\/empresa\/gate2brain-s-l\/\" target=\"_blank\" rel=\"noopener\">Gate2Brain<\/a> -based in the Barcelona Science Park and focused on enhancing drug delivery to the brain through its cutting-edge technology platform- has achieved a significant milestone. The European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its innovative product, G2B-002, a crucial step forward, accelerating its progress toward clinical trials for pediatric brain tumors treatment.<\/strong><\/p>\n<p>Gate2Brain\u2019s most advanced product, G2B-002, is based on a peptide transport system that delivers an anti-cancer agent that targets diffuse intrinsic pontine glioma (DIPG) and pediatric glioblastoma (pGBM), two aggressive brain tumors that are among the leading causes of childhood cancer mortality.<\/p>\n<p>With a research programme initially focused on pediatric brain tumors.\u00a0 Gate2Brain aims to leverage EMA\u2019s recognition to advance G2B-002 to clinical trials and pave the way for a new era of treatment options in a high unmet need area.<\/p>\n<p>We are moving toward clinical trials that could transform the treatment of pediatric brain tumors\u201d, explains <strong>Meritxell Teixid\u00f3<\/strong>, CEO of Gate2Brain, underscoring the company\u2019s strong commitment to pediatric patients and their families.<\/p>\n<h3><strong>A Boost to Transform Pediatric Brain Cancer Treatment<\/strong><\/h3>\n<p>Gate2Brain -founded in 2020 as a\u00a0spin-off from the Institute for Research in Biomedicine (<a href=\"https:\/\/www.pcb.ub.edu\/en\/empresa\/institut-de-recerca-biomedica-irb-barcelona\/\" target=\"_blank\" rel=\"noopener\">IRB Barcelona<\/a>), the University of Barcelona (<a href=\"https:\/\/www.ub.edu\/web\/ub\/en\/index.html?\" target=\"_blank\" rel=\"noopener noreferrer\">UB<\/a>) and the Sant Joan de D\u00e9u Research Institute (<a href=\"https:\/\/www.irsjd.org\/ca\/\" target=\"_blank\" rel=\"noopener noreferrer\">IRSJD<\/a>)- Hospital Sant Joan de D\u00e9u (<a href=\"https:\/\/www.sjdhospitalbarcelona.org\/en\" target=\"_blank\" rel=\"noopener noreferrer\">SJD<\/a>)- has developed a patented technology that allows drugs to cross the blood-brain barrier (BBB) more effectively, increasing precision and efficacy in treating brain tumors.<\/p>\n<p>G2B-002, Gate2Brain&#8217;s most advanced product and a proof of concept for its technology, is based on a peptide transport system that delivers an anti-cancer agent. This system has demonstrated efficacy against pediatric brain tumors with an intact BBB, such as pediatric glioblastoma (pGBM) and diffuse intrinsic pontine glioma (DIPG), the first conditions to benefit from this technology.<\/p>\n<p>Furthermore, these results show potential applications for other therapeutic agents and biological barriers, with significant clinical implications.<\/p>\n<p><strong>\u00bb For further information:<\/strong> <a href=\"https:\/\/gate2brain.com\/gate2brain-receives-ema-orphan-drug-designation-for-its-groundbreaking-pediatric-cancer-treatment\/\" target=\"_blank\" rel=\"noopener\">Gate2Brain website [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gate2Brain -based in the Barcelona Science Park and focused on enhancing drug delivery to the brain through its cutting-edge technology platform- has achieved a significant milestone. The European Medicines Agency&#8230;<\/p>\n","protected":false},"author":4,"featured_media":100060,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[35],"tags":[],"class_list":["post-100066","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gate2Brain receives EMA Orphan Drug Designation for groundbreaking pediatric cancer treatment - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gate2Brain receives EMA Orphan Drug Designation for groundbreaking pediatric cancer treatment - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Gate2Brain -based in the Barcelona Science Park and focused on enhancing drug delivery to the brain through its cutting-edge technology platform- has achieved a significant milestone. The European Medicines Agency...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-20T12:41:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-20T14:33:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/11\/Meritxell-Teixido-Gate2Brain-cerebro.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"339\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Azucena Berea\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Azucena Berea\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\\\/\"},\"author\":{\"name\":\"Azucena Berea\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/810a86a39effe6bf90f9ab918ca43239\"},\"headline\":\"Gate2Brain receives EMA Orphan Drug Designation for groundbreaking pediatric cancer treatment\",\"datePublished\":\"2024-11-20T12:41:57+00:00\",\"dateModified\":\"2024-11-20T14:33:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\\\/\"},\"wordCount\":346,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Meritxell-Teixido-Gate2Brain-cerebro.jpg\",\"articleSection\":[\"COMPANIES\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\\\/\",\"name\":\"Gate2Brain receives EMA Orphan Drug Designation for groundbreaking pediatric cancer treatment - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Meritxell-Teixido-Gate2Brain-cerebro.jpg\",\"datePublished\":\"2024-11-20T12:41:57+00:00\",\"dateModified\":\"2024-11-20T14:33:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/810a86a39effe6bf90f9ab918ca43239\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Meritxell-Teixido-Gate2Brain-cerebro.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Meritxell-Teixido-Gate2Brain-cerebro.jpg\",\"width\":900,\"height\":339},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gate2Brain receives EMA Orphan Drug Designation for groundbreaking pediatric cancer treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/810a86a39effe6bf90f9ab918ca43239\",\"name\":\"Azucena Berea\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g\",\"caption\":\"Azucena Berea\"},\"sameAs\":[\"https:\\\/\\\/www.pcb.ub.edu\"],\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/aberea\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gate2Brain receives EMA Orphan Drug Designation for groundbreaking pediatric cancer treatment - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Gate2Brain receives EMA Orphan Drug Designation for groundbreaking pediatric cancer treatment - Parc Cient\u00edfic de Barcelona","og_description":"Gate2Brain -based in the Barcelona Science Park and focused on enhancing drug delivery to the brain through its cutting-edge technology platform- has achieved a significant milestone. The European Medicines Agency...","og_url":"https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2024-11-20T12:41:57+00:00","article_modified_time":"2024-11-20T14:33:46+00:00","og_image":[{"width":900,"height":339,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/11\/Meritxell-Teixido-Gate2Brain-cerebro.jpg","type":"image\/jpeg"}],"author":"Azucena Berea","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Azucena Berea","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/"},"author":{"name":"Azucena Berea","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/810a86a39effe6bf90f9ab918ca43239"},"headline":"Gate2Brain receives EMA Orphan Drug Designation for groundbreaking pediatric cancer treatment","datePublished":"2024-11-20T12:41:57+00:00","dateModified":"2024-11-20T14:33:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/"},"wordCount":346,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/11\/Meritxell-Teixido-Gate2Brain-cerebro.jpg","articleSection":["COMPANIES"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/","url":"https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/","name":"Gate2Brain receives EMA Orphan Drug Designation for groundbreaking pediatric cancer treatment - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/11\/Meritxell-Teixido-Gate2Brain-cerebro.jpg","datePublished":"2024-11-20T12:41:57+00:00","dateModified":"2024-11-20T14:33:46+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/810a86a39effe6bf90f9ab918ca43239"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/11\/Meritxell-Teixido-Gate2Brain-cerebro.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/11\/Meritxell-Teixido-Gate2Brain-cerebro.jpg","width":900,"height":339},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/gate2brain-receives-ema-orphan-drug-designation-for-groundbreaking-pediatric-cancer-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Gate2Brain receives EMA Orphan Drug Designation for groundbreaking pediatric cancer treatment"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/810a86a39effe6bf90f9ab918ca43239","name":"Azucena Berea","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g","caption":"Azucena Berea"},"sameAs":["https:\/\/www.pcb.ub.edu"],"url":"https:\/\/www.pcb.ub.edu\/en\/author\/aberea\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/100066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=100066"}],"version-history":[{"count":3,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/100066\/revisions"}],"predecessor-version":[{"id":100071,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/100066\/revisions\/100071"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/100060"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=100066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=100066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=100066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}